tiprankstipranks
Trending News
More News >
Xvivo Perfusion AB (XVIPF)
OTHER OTC:XVIPF
Advertisement

Xvivo Perfusion AB (XVIPF) Price & Analysis

Compare
11 Followers

XVIPF Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

4.65%92.70%
Insiders
― Other Institutional Investors
92.70% Public Companies and
Individual Investors

XVIPF FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was $21.64 and its highest was $52.48 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Xvivo Perfusion AB’s market cap is $663.55M.
      When is Xvivo Perfusion AB’s upcoming earnings report date?
      Xvivo Perfusion AB’s upcoming earnings report date is Oct 23, 2025 which is in 100 days.
        How were Xvivo Perfusion AB’s earnings last quarter?
        Currently, no data Available
        Is Xvivo Perfusion AB overvalued?
        According to Wall Street analysts Xvivo Perfusion AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Xvivo Perfusion AB pay dividends?
          Xvivo Perfusion AB does not currently pay dividends.
          What is Xvivo Perfusion AB’s EPS estimate?
          Xvivo Perfusion AB’s EPS estimate is 0.06.
            How many shares outstanding does Xvivo Perfusion AB have?
            Xvivo Perfusion AB has 31,499,470 shares outstanding.
              What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Xvivo Perfusion AB?
              Currently, no hedge funds are holding shares in XVIPF

              Company Description

              Xvivo Perfusion AB

              Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
              Similar Stocks
              Company
              Price & Change
              Follow
              Vitrolife AB
              Arjo AB
              Biotage AB
              RaySearch Laboratories AB
              Surgical Science Sweden AB
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis